All In Biotech

Drug Trial Radar · NCT02041195

Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese Patients

A Staged, Phase 1b/Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety and Efficacy of RM-493, a Melanocortin 4 Receptor (MC4R) Agonist in Obese Patients Using a Once or Twice Daily Sub-Cutaneous Injection Formulation

Last checked: Nov 20, 2026Latest source record: Aug 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

99

Actual

Start

Jan 2014

Primary completion

Aug 2014

Study completion Dec 2014

Sponsor

Lead sponsor
Rhythm Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Jan 20, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effects of a new daily subcutaneous (SC) injectable formulation of setmelanotide (RM-493) in healthy participants with obesity on mean percent body weight loss and other weight loss parameters, as well as pharmacokinetic (PK) profile. The study is designed to evaluate the efficacy and tolerability of setmelanotide administered once or twice daily. The study drug (setmelanotide and placebo) will be administered in a blinded fashion.

Conditions

  • Overweight and Obesity

Interventions

  • SetmelanotideDrug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Body Weight - Stage ATime frame: Baseline
  2. Percent Change From Baseline in Body Weight at Week 12 - Stage ATime frame: Baseline, Week 12
  3. Body Weight - Stage BTime frame: Baseline
  4. Percent Change From Baseline in Body Weight at Week 12 - Stage BTime frame: Baseline, Week 12
  5. Body Weight - Stage CTime frame: Baseline
  6. Percent Change From Baseline in Body Weight at Week 12 - Stage CTime frame: Baseline, Week 12
  7. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) - Stage ATime frame: From first dose up to Day 114
  8. Number of Participants With TEAEs - Stage BTime frame: From first dose up to Day 114
  9. Number of Participants With TEAEs - Stage CTime frame: From first dose up to Day 114

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Dallas, Texas

  • Site not named

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.